Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04232878 · ClinicalTrials.gov registry record · Phase 1
A Single Ascending Dose Trial of CVL-936 in Healthy Subjects
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04232878 is a Phase 1 study that was terminated before completion, run by Cerevel Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT04232878, a Phase 1 study, was terminated before completion, sponsored by Cerevel Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
Interventions
- DRUG Matching Placebo
- DRUG CVL-936
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04232878
The ClinicalTrials.gov registry entry for NCT04232878 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cerevel Therapeutics, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT04232878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04232878 about?
NCT04232878 is a clinical study titled "A Single Ascending Dose Trial of CVL-936 in Healthy Subjects". The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CVL-936 following single ascending oral doses in healthy subjects.
What is the current status of trial NCT04232878?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-12-16. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT04232878?
The interventions under investigation include: Matching Placebo (DRUG), CVL-936 (DRUG).
Who is sponsoring clinical trial NCT04232878?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.